Click the image below to view the animated version of this cover.

Created by: Maximilian Strobl

Issue 169: To mix things, I thought I would tell you a little about myself today. I’m very interested in adaptive cancer therapy – the idea to leverage competition between drug-sensitive and resistant cells through strategic treatment adaptation. The attached simulations show a simple agent-based model of adaptive therapy (written in HAL) under increasing rates of cell turnover (left to right) and resistance costs (top to bottom). Importantly, you can see that the time for which the resistant colonies (pink) can be contained by sensitive cells (green) is modulated by a combination of both cost and turnover. As such, our research suggests that the rate of cell turnover in a tumor may be an important factor to consider when deciding whether and how to apply adaptive therapy. To read more about this work, see our paper here and our recent pre-print on the biorxiv.